8-K
filed July 30, 2024, 7:59 PM ET
CIK 0001394319
other material
confidence high
sentiment negative
materiality 1.00
Tracon Pharmaceuticals, Inc.: restructuring charge — TRACON Pharmaceuticals to wind down operations, terminate employees, seek dissolution
Tracon Pharmaceuticals, Inc.
- Board approves reduction-in-force of substantially all employees effective July 31, 2024; expects ~$1.7M in severance costs.
- Board approves Plan of Dissolution and liquidation, subject to stockholder vote at a special meeting.
- All directors resign; CEO Charles Theuer and CFO Scott Brown depart on July 31, 2024.
- Appoints Craig R. Jalbert as President, CEO, Secretary, Treasurer, and sole Board member to oversee wind-down.
- Jalbert, a distressed-business specialist, will receive $10K/month until dissolution vote, then $50K/year for 3 years.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Craig R. Jalbert was appointed as President, Chief Executive Officer, Secretary, Treasurer, and sole member of the Board at Tracon Pharmaceuticals, Inc..
- Action
- appointed
- Role
- President, Chief Executive Officer, Secretary, Treasurer, and sole member of the Board
Exact text from the filing
On July 30, 2024, the Board appointed Craig R. Jalbert, age 62, as the Company’s President, Chief Executive Officer, Secretary, Treasurer, and sole member of the Board, effective July 31, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Carol C. Lam resigned as Director at Tracon Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On July 30, 2024, in connection with the planned wind down of the Company’s operations, Charles P. Theuer, M.D., Ph.D., Lisa Johnson-Pratt, M.D., Carol C. Lam. J.D., William R. LaRue, Martin A. Mattingly, Pharm.D., Saundra Pelletier, J. Rainer Twiford, J.D., Ph.D. and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the Board and all committees thereof, effective July 31, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Scott B. Brown departed as Chief Financial Officer and Secretary at Tracon Pharmaceuticals, Inc..
- Action
- ceased serving
- Role
- Chief Financial Officer and Secretary
Exact text from the filing
In connection with the Reduction in Force, Scott B. Brown, CPA, Chief Financial Officer and Secretary will cease serving as an officer of the Company effective July 31, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Lisa Johnson-Pratt resigned as Director at Tracon Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On July 30, 2024, in connection with the planned wind down of the Company’s operations, Charles P. Theuer, M.D., Ph.D., Lisa Johnson-Pratt, M.D., Carol C. Lam. J.D., William R. LaRue, Martin A. Mattingly, Pharm.D., Saundra Pelletier, J. Rainer Twiford, J.D., Ph.D. and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the Board and all committees thereof, effective July 31, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Saundra Pelletier resigned as Director at Tracon Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On July 30, 2024, in connection with the planned wind down of the Company’s operations, Charles P. Theuer, M.D., Ph.D., Lisa Johnson-Pratt, M.D., Carol C. Lam. J.D., William R. LaRue, Martin A. Mattingly, Pharm.D., Saundra Pelletier, J. Rainer Twiford, J.D., Ph.D. and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the Board and all committees thereof, effective July 31, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Charles P. Theuer resigned as Director at Tracon Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On July 30, 2024, in connection with the planned wind down of the Company’s operations, Charles P. Theuer, M.D., Ph.D., Lisa Johnson-Pratt, M.D., Carol C. Lam. J.D., William R. LaRue, Martin A. Mattingly, Pharm.D., Saundra Pelletier, J. Rainer Twiford, J.D., Ph.D. and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the Board and all committees thereof, effective July 31, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
J. Rainer Twiford resigned as Director at Tracon Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On July 30, 2024, in connection with the planned wind down of the Company’s operations, Charles P. Theuer, M.D., Ph.D., Lisa Johnson-Pratt, M.D., Carol C. Lam. J.D., William R. LaRue, Martin A. Mattingly, Pharm.D., Saundra Pelletier, J. Rainer Twiford, J.D., Ph.D. and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the Board and all committees thereof, effective July 31, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Stephen T. Worland resigned as Director at Tracon Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On July 30, 2024, in connection with the planned wind down of the Company’s operations, Charles P. Theuer, M.D., Ph.D., Lisa Johnson-Pratt, M.D., Carol C. Lam. J.D., William R. LaRue, Martin A. Mattingly, Pharm.D., Saundra Pelletier, J. Rainer Twiford, J.D., Ph.D. and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the Board and all committees thereof, effective July 31, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Martin A. Mattingly resigned as Director at Tracon Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On July 30, 2024, in connection with the planned wind down of the Company’s operations, Charles P. Theuer, M.D., Ph.D., Lisa Johnson-Pratt, M.D., Carol C. Lam. J.D., William R. LaRue, Martin A. Mattingly, Pharm.D., Saundra Pelletier, J. Rainer Twiford, J.D., Ph.D. and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the Board and all committees thereof, effective July 31, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Charles P. Theuer resigned as President and Chief Executive Officer at Tracon Pharmaceuticals, Inc..
- Action
- resigned
- Role
- President and Chief Executive Officer
Exact text from the filing
On July 30, 2024, Charles P. Theuer, M.D., Ph.D., tendered his resignation as the Company’s President and Chief Executive Officer, to be effective as of July 31, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
William R. LaRue resigned as Director at Tracon Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On July 30, 2024, in connection with the planned wind down of the Company’s operations, Charles P. Theuer, M.D., Ph.D., Lisa Johnson-Pratt, M.D., Carol C. Lam. J.D., William R. LaRue, Martin A. Mattingly, Pharm.D., Saundra Pelletier, J. Rainer Twiford, J.D., Ph.D. and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the Board and all committees thereof, effective July 31, 2024.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
Tracon Pharmaceuticals, Inc. announced a restructuring with charges of approximately $1.7 million (substantially all of its employees).
- Type
- restructuring
- Charge
- approximately $1.7 million
- Headcount
- substantially all of its employees
Exact text from the filing
On July 26, 2024, the Board of Directors (the “Board”) of TRACON Pharmaceuticals, Inc. (the “Company”) unanimously approved a reduction-in-force (the “Reduction in Force”) of substantially all of its employees to be effective on July 31, 2024, in connection with the planned wind down of the Company’s operations. The Company expects to incur one-time charges and cash expenditures associated with the workforce reduction of approximately $1.7 million, primarily related to employee wages and severance payments, benefits and related termination costs.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.